[go: up one dir, main page]

NO20054868D0 - CaSr antagonist - Google Patents

CaSr antagonist

Info

Publication number
NO20054868D0
NO20054868D0 NO20054868A NO20054868A NO20054868D0 NO 20054868 D0 NO20054868 D0 NO 20054868D0 NO 20054868 A NO20054868 A NO 20054868A NO 20054868 A NO20054868 A NO 20054868A NO 20054868 D0 NO20054868 D0 NO 20054868D0
Authority
NO
Norway
Prior art keywords
casr antagonist
casr
antagonist
Prior art date
Application number
NO20054868A
Other languages
English (en)
Other versions
NO20054868L (no
Inventor
Yuko Shinagawa
Teruhiko Inoue
Toshihiro Kiguchi
Taku Ikenogami
Naoki Ogawa
Kenji Fukuda
Takashi Nakagawa
Masanori Shindo
Yuki Soejima
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO20054868D0 publication Critical patent/NO20054868D0/no
Publication of NO20054868L publication Critical patent/NO20054868L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
NO20054868A 2003-04-23 2005-10-21 CaSr antagonist NO20054868L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003119131 2003-04-23
PCT/JP2004/005886 WO2004094362A1 (ja) 2003-04-23 2004-04-23 CaSRアンタゴニスト

Publications (2)

Publication Number Publication Date
NO20054868D0 true NO20054868D0 (no) 2005-10-21
NO20054868L NO20054868L (no) 2005-12-20

Family

ID=33308093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054868A NO20054868L (no) 2003-04-23 2005-10-21 CaSr antagonist

Country Status (30)

Country Link
US (4) US7304174B2 (no)
EP (3) EP2189439A3 (no)
JP (1) JP3751312B2 (no)
KR (1) KR100696927B1 (no)
CN (2) CN101723921A (no)
AR (1) AR044075A1 (no)
AT (1) ATE452121T1 (no)
AU (1) AU2004232604C1 (no)
BR (1) BRPI0407097A (no)
CA (1) CA2513738C (no)
CL (1) CL2004000868A1 (no)
CO (1) CO5640091A2 (no)
CY (1) CY1109880T1 (no)
DE (1) DE602004024668D1 (no)
DK (1) DK1619180T3 (no)
ES (1) ES2337576T3 (no)
HR (1) HRP20100042T1 (no)
IL (1) IL169575A (no)
MX (1) MXPA05007609A (no)
MY (1) MY138734A (no)
NO (1) NO20054868L (no)
NZ (1) NZ541188A (no)
PE (1) PE20050460A1 (no)
PL (1) PL1619180T3 (no)
PT (1) PT1619180E (no)
RU (1) RU2315036C2 (no)
SI (1) SI1619180T1 (no)
TW (1) TWI329628B (no)
WO (1) WO2004094362A1 (no)
ZA (1) ZA200505587B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
WO2004106280A1 (ja) * 2003-05-28 2004-12-09 Japan Tobacco Inc. CaSRアンタゴニスト
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20070155819A1 (en) * 2004-02-06 2007-07-05 Marquis Robert W Jr Calcilytic compounds
BRPI0710814A2 (pt) 2006-04-20 2011-08-16 Amgen Inc formulações de emulsão estável
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
EP2292592B1 (en) * 2008-06-05 2012-09-05 Asahi Kasei Pharma Corporation Sulfonamide compound and application thereof
RU2474572C1 (ru) 2008-12-24 2013-02-10 Дайити Санкио Компани, Лимитед Инданильные соединения
CA2748249C (en) * 2008-12-24 2013-07-02 Daiichi Sankyo Company, Limited Cyclic amine compounds
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2010103429A1 (en) * 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
JP5250693B2 (ja) * 2009-03-26 2013-07-31 日本たばこ産業株式会社 カルボン酸化合物の製造方法
WO2010113860A1 (ja) * 2009-03-31 2010-10-07 第一三共株式会社 ビフェニル-環状アミン化合物
JP2012528086A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
EP2435400A2 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2012069420A2 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
US20130267516A1 (en) 2010-11-26 2013-10-10 Leo Pharma A/S Substituted cyclopentyl-azines as casr-active compounds
RU2013128968A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительного рецептора
US20130245084A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
GB201113538D0 (en) * 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
CN104583177B (zh) * 2012-08-27 2016-09-07 卢平亚特兰蒂斯控股有限公司 作为钙敏感受体调节剂的芳基烷基胺化合物
MX393292B (es) 2016-06-13 2025-03-11 Syneurx Int Taiwan Corp Uso de benzoato de litio para tratar trastornos del sistema nervioso central
KR20220110789A (ko) * 2019-12-09 2022-08-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 칼슘 감지 수용체 효능제 화합물 및 이의 응용
US20220040112A1 (en) 2020-08-04 2022-02-10 Calcilytix Therapeutics, Inc. Formulations of triphenyl calcilytic compounds
WO2022060987A1 (en) 2020-09-18 2022-03-24 Calcilytix Therapeutics, Inc. Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)
TW202506101A (zh) 2023-04-21 2025-02-16 美商柯西立提克斯療法有限公司 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633760A (no) * 1963-06-18
DD207203A1 (de) * 1982-06-21 1984-02-22 Peter Meisel Verfahren zur herstellung von epoxypropylethern
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
US5276008A (en) * 1990-08-09 1994-01-04 Bayer Aktiengesellschaft Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones
RU2147574C1 (ru) * 1991-08-23 2000-04-20 Эн-Пи-Эс Фармасьютикалз, Инк. Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
WO1997037967A1 (en) * 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
ES2171839T3 (es) * 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
AR018177A1 (es) 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
US20020052509A1 (en) 1998-04-08 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds and method of use
US6334338B1 (en) * 1998-07-02 2002-01-01 Lucent Technologies Inc. Sol gel process of making a fiber preform with removal of oxide particles
US6335338B1 (en) 1998-08-12 2002-01-01 Smithkline Beecham Corporation Calcilytic compounds
JP2002522499A (ja) 1998-08-12 2002-07-23 スミスクライン・ビーチャム・コーポレイション カルシウム分解化合物
ATE277931T1 (de) * 1998-10-23 2004-10-15 Hoffmann La Roche Bicyclische stickstoffheteroaryl verbindungen
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
JP2003508586A (ja) * 1999-08-27 2003-03-04 ザ、プロクター、エンド、ギャンブル、カンパニー 迅速に作用する処方成分、それらの成分を使用する組成物および洗濯方法
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
AR030684A1 (es) 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
AU7692301A (en) 2000-07-21 2002-02-05 Smithkline Beecham Corp Calcilytic compounds
WO2002014259A1 (en) 2000-08-11 2002-02-21 Japan Tobacco Inc. Calcium receptor antagonists
DE60124148T2 (de) 2000-10-25 2007-09-06 Smithkline Beecham Corp. Kalzilytische verbindungen
JP2004519428A (ja) 2000-10-25 2004-07-02 スミスクライン・ビーチャム・コーポレイション カルシライティック化合物
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
WO2004106280A1 (ja) 2003-05-28 2004-12-09 Japan Tobacco Inc. CaSRアンタゴニスト

Also Published As

Publication number Publication date
JP3751312B2 (ja) 2006-03-01
WO2004094362A1 (ja) 2004-11-04
EP1619180B1 (en) 2009-12-16
EP1619180A4 (en) 2006-05-24
NZ541188A (en) 2008-01-31
RU2005123985A (ru) 2006-01-27
ZA200505587B (en) 2006-09-27
BRPI0407097A (pt) 2006-01-24
CN100577633C (zh) 2010-01-06
ES2337576T3 (es) 2010-04-27
CO5640091A2 (es) 2006-05-31
AU2004232604C1 (en) 2008-06-05
CA2513738C (en) 2010-04-06
ATE452121T1 (de) 2010-01-15
DK1619180T3 (da) 2010-03-29
EP2189439A3 (en) 2011-05-04
JPWO2004094362A1 (ja) 2006-07-13
KR20050094047A (ko) 2005-09-26
NO20054868L (no) 2005-12-20
CN1741984A (zh) 2006-03-01
EP1619180A1 (en) 2006-01-25
RU2315036C2 (ru) 2008-01-20
PE20050460A1 (es) 2005-07-08
EP2189439A2 (en) 2010-05-26
AR044075A1 (es) 2005-08-24
US7304174B2 (en) 2007-12-04
KR100696927B1 (ko) 2007-03-20
AU2004232604B8 (en) 2004-11-04
CA2513738A1 (en) 2004-11-04
US20050032796A1 (en) 2005-02-10
EP2308828A2 (en) 2011-04-13
IL169575A0 (en) 2007-07-04
MY138734A (en) 2009-07-31
AU2004232604A8 (en) 2004-11-04
US20120301552A1 (en) 2012-11-29
EP2308828A3 (en) 2013-05-22
MXPA05007609A (es) 2005-09-30
IL169575A (en) 2011-07-31
CY1109880T1 (el) 2014-09-10
PL1619180T3 (pl) 2010-05-31
SI1619180T1 (sl) 2010-04-30
DE602004024668D1 (de) 2010-01-28
TWI329628B (en) 2010-09-01
CL2004000868A1 (es) 2005-01-21
HRP20100042T1 (hr) 2010-02-28
AU2004232604B2 (en) 2007-09-13
TW200505823A (en) 2005-02-16
US20080255042A1 (en) 2008-10-16
AU2004232604A1 (en) 2004-11-04
CN101723921A (zh) 2010-06-09
HK1083096A1 (en) 2006-06-23
PT1619180E (pt) 2009-12-29
US20090326058A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
ATE452121T1 (de) Casr-antagonist
ATE363383T1 (de) Schlingenware
DE50300325D1 (de) Vaginalpflegezusammensetzung
DE502004001683D1 (de) Kabelführung
DE602004031845D1 (de) Ng
DE602004001197D1 (de) Umverpackungsschrumpffolie
AT502792A5 (de) Düsenanpressvorrichtung
DE112004000620D2 (de) Struktoguss
DE10355350A8 (de) Elektromodul
DE502004000672D1 (de) Pigmentpreparationen
DE502004001524D1 (de) Hydrolager
ATA662003A (de) Trink-mundstück
ATE446959T1 (de) Chromenonindole
DE602004018799D1 (de) Ng
DE502004002978D1 (de) N-biarylamide
DE502004001629D1 (de) Bremsenprüfstand
ATE444953T1 (de) Substituierte spirobenzazepine
DE502004003122D1 (de) Hydrolager
DE502004000518D1 (de) Mitgängergabelhubwagen
DE502004005162D1 (de) Leistungsregelvorricthung
DE10394329D2 (de) Mäanderstent
ATE406350T1 (de) Prolinylarylacetamide
DE10329218B4 (de) Hotflue
DE502004002771D1 (de) Umlenkhebel
DE502004002619D1 (de) Flaschenverschluss

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application